GNKS356

(Immune modulating drug/DNA nucleotide drug)

Indication

GNKS356 is a DNA based immune modulating drug candidate targeting for autoimmune diseases including SLE (Systemic Lupus Erythematosus), psoriasis and RA (Rheumatoid Arthritis).
In patients suffering from SLE or RA, inflammation occurs when over-activated immune system mistakenly attacks its own healthy tissues. GNKS356 can inhibit such inflammation to treat autoimmune diseases.

Mode of action

TLR9 is activated in the patients suffering from SLE and TLR9 activation induces unwilling immune reactions. Thus, suppression of TLR9 function is a promising strategy to treat autoimmune diseases.
GNKS356 binds to TLR9 and suppresses TLR9 induced immune reactions.

Partnering Opportunities

If you are interested in collaborating with SBI Biotech,please contact our business development team.

Direct to Research & Development Dept.
web_sbibt@sbigroup.co.jp
Phone: +81-3-6229-0831

 Back to top